JP2014158485A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014158485A5 JP2014158485A5 JP2014080445A JP2014080445A JP2014158485A5 JP 2014158485 A5 JP2014158485 A5 JP 2014158485A5 JP 2014080445 A JP2014080445 A JP 2014080445A JP 2014080445 A JP2014080445 A JP 2014080445A JP 2014158485 A5 JP2014158485 A5 JP 2014158485A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- erbb3
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 329
- 150000001413 amino acids Chemical class 0.000 claims 31
- 238000012217 deletion Methods 0.000 claims 12
- 230000037430 deletion Effects 0.000 claims 12
- 238000006467 substitution reaction Methods 0.000 claims 12
- 238000007792 addition Methods 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 230000006229 amino acid addition Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477089P | 2011-04-19 | 2011-04-19 | |
| US61/477,089 | 2011-04-19 | ||
| US201161539297P | 2011-09-26 | 2011-09-26 | |
| US61/539,297 | 2011-09-26 | ||
| US201161558192P | 2011-11-10 | 2011-11-10 | |
| US61/558,192 | 2011-11-10 | ||
| US201261619244P | 2012-04-02 | 2012-04-02 | |
| US61/619,244 | 2012-04-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506549A Division JP5588086B2 (ja) | 2011-04-19 | 2012-04-19 | 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014158485A JP2014158485A (ja) | 2014-09-04 |
| JP2014158485A5 true JP2014158485A5 (enExample) | 2015-06-11 |
| JP6214453B2 JP6214453B2 (ja) | 2017-10-18 |
Family
ID=47021510
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506549A Expired - Fee Related JP5588086B2 (ja) | 2011-04-19 | 2012-04-19 | 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体 |
| JP2014080445A Expired - Fee Related JP6214453B2 (ja) | 2011-04-19 | 2014-04-09 | 単一特異性および二重特異性抗ｉｇｆ‐１ｒ抗体および抗ｅｒｂｂ３抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506549A Expired - Fee Related JP5588086B2 (ja) | 2011-04-19 | 2012-04-19 | 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8476409B2 (enExample) |
| EP (2) | EP3214096A3 (enExample) |
| JP (2) | JP5588086B2 (enExample) |
| KR (2) | KR20140138353A (enExample) |
| CN (2) | CN105884900A (enExample) |
| AU (2) | AU2012245491C1 (enExample) |
| BR (1) | BR112013027021A2 (enExample) |
| CA (1) | CA2833643A1 (enExample) |
| DK (1) | DK2699602T3 (enExample) |
| ES (1) | ES2625818T3 (enExample) |
| HK (1) | HK1223383A1 (enExample) |
| HR (1) | HRP20170713T1 (enExample) |
| HU (1) | HUE034276T2 (enExample) |
| IL (1) | IL228957A0 (enExample) |
| MX (2) | MX346486B (enExample) |
| PL (1) | PL2699602T3 (enExample) |
| PT (1) | PT2699602T (enExample) |
| SI (1) | SI2699602T1 (enExample) |
| TW (1) | TWI631136B (enExample) |
| WO (1) | WO2012145507A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2678181C (en) | 2007-02-16 | 2016-12-13 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
| AU2010306774A1 (en) * | 2009-10-14 | 2012-05-03 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof |
| AU2011224186C1 (en) | 2010-03-11 | 2015-04-02 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| MX346486B (es) * | 2011-04-19 | 2017-03-22 | Merrimack Pharmaceuticals Inc | Anticuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos. |
| EP2833915A1 (en) * | 2012-04-02 | 2015-02-11 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| CN104341504B (zh) * | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | 双特异性抗体 |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| EP3107578A2 (en) * | 2014-02-20 | 2016-12-28 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith |
| RS61379B1 (sr) * | 2014-04-25 | 2021-02-26 | Pf Medicament | Antitelo na igf-1r i njegova upotreba kao usmerenog nosioca za lečenje kancera |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| US20180169230A1 (en) | 2015-05-29 | 2018-06-21 | Merrimack Pharmaceuticals, Inc. | Combination cancer therapies |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| WO2017031442A1 (en) | 2015-08-20 | 2017-02-23 | Merrimack Pharmaceuticals, Inc. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| MX385425B (es) | 2015-08-21 | 2025-03-18 | Ipsen Biopharm Ltd | Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico. |
| RU2732567C2 (ru) | 2015-10-16 | 2020-09-21 | Ипсен Биофарм Лтд. | Стабилизированные фармацевтические композиции камптотецина |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| US20170233491A1 (en) | 2016-01-19 | 2017-08-17 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment |
| CN109310755A (zh) * | 2016-02-02 | 2019-02-05 | 卡德门企业有限公司 | Pd-l1和kdr的双特异性结合蛋白 |
| US10723857B1 (en) * | 2016-04-15 | 2020-07-28 | United States Of America As Represented By The Administrator Of National Aeronautics And Space Administration | Polyimide aerogels with reduced shrinkage from isothermal aging |
| WO2018045256A1 (en) * | 2016-09-02 | 2018-03-08 | Merrimack Pharmaceuticals, Inc. | Combination of an erbb3 inhibitor, topoisomerase i inhibitor, and an alkylating agent to treat cancer |
| JP6825284B2 (ja) * | 2016-09-21 | 2021-02-03 | カシオ計算機株式会社 | イメージ作成装置、イメージ作成方法、及び、プログラム |
| SG10201912338RA (en) | 2016-11-02 | 2020-02-27 | Ipsen Biopharm Ltd | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| ES2948647T3 (es) * | 2017-05-04 | 2023-09-15 | Acceleron Pharma Inc | Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas |
| CN107602702A (zh) | 2017-09-22 | 2018-01-19 | 生标（上海）医疗器械科技有限公司 | 一种同时靶向人p185和血管内皮生长因子的抗体及其应用 |
| GB201804094D0 (en) * | 2018-03-14 | 2018-04-25 | Ultrahuman Thirteen Ltd | ERBB3 Binding agents |
| US10654944B2 (en) | 2018-04-10 | 2020-05-19 | Y-Biologics Inc. | Cell engaging binding molecules |
| JP7397874B2 (ja) | 2018-08-30 | 2023-12-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
| CN120535649A (zh) | 2018-08-30 | 2025-08-26 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| EP4592314A3 (en) | 2018-08-30 | 2025-11-05 | ImmunityBio, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| WO2020257639A1 (en) | 2019-06-21 | 2020-12-24 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| EP4103599A1 (en) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| CA3169231A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
| US12187763B2 (en) | 2020-02-11 | 2025-01-07 | Immunitybio, Inc. | Chromatography resin and uses thereof |
| CN113512116B (zh) * | 2020-04-10 | 2022-09-20 | 苏州普乐康医药科技有限公司 | 一种抗igf-1r抗体及其应用 |
| AU2021262794A1 (en) | 2020-04-29 | 2022-11-24 | Immunitybio, Inc. | Anti-CD26 proteins and uses thereof |
| EP4157460A1 (en) | 2020-06-01 | 2023-04-05 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| CN118043351A (zh) * | 2021-08-31 | 2024-05-14 | 上海医药集团股份有限公司 | 靶向Siglec15的抗原结合蛋白及其用途 |
| EP4486368A1 (en) | 2022-03-02 | 2025-01-08 | ImmunityBio, Inc. | Method of treating pancreatic cancer |
| CN120623322B (zh) * | 2025-08-14 | 2025-12-05 | 成都蓉生药业有限责任公司 | 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| NZ331360A (en) | 1996-03-27 | 2000-03-27 | Genentech Inc | an antibody which binds to a ErbB3 protein and reduces heregulin-induced formation of a ErbB2-ErbB3 protein complex |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| CA2424602C (en) | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
| WO2002030954A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Method of purifying antibody |
| EP1399483B1 (en) * | 2001-01-05 | 2010-04-14 | Pfizer Inc. | Antibodies to insulin-like growth factor i receptor |
| CA2442801A1 (en) | 2001-04-02 | 2002-10-10 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with gntiii |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| WO2005016970A2 (en) * | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| BRPI0611445A2 (pt) | 2005-05-09 | 2010-09-08 | Glycart Biotechnology Ag | molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica |
| JP5374359B2 (ja) * | 2006-03-17 | 2013-12-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 安定化されたポリペプチド化合物 |
| AU2007353412A1 (en) * | 2006-11-21 | 2008-11-20 | Fox Chase Cancer Center | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
| CA2678181C (en) | 2007-02-16 | 2016-12-13 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
| US20100166747A1 (en) * | 2007-03-02 | 2010-07-01 | Beltran Pedro J | Methods and compositions for treating tumor diseases |
| WO2009032782A2 (en) * | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
| WO2009126920A2 (en) | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| BRPI0917871A2 (pt) | 2008-08-15 | 2017-06-20 | Merrimack Pharmaceuticals Inc | agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico |
| US8362215B2 (en) | 2009-04-29 | 2013-01-29 | Trellis Bioscience, Llc | Antibodies immunoreactive with heregulin-coupled HER3 |
| RU2570633C2 (ru) * | 2009-05-27 | 2015-12-10 | Ф.Хоффманн-Ля Рош Аг | Три- или тетраспецифические антитела |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CN103002912A (zh) | 2009-08-21 | 2013-03-27 | 梅里麦克制药股份有限公司 | 针对ErbB3的胞外结构域的抗体及其用途 |
| CN102612524A (zh) | 2009-09-01 | 2012-07-25 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
| AU2010306774A1 (en) * | 2009-10-14 | 2012-05-03 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof |
| MA33892B1 (fr) | 2009-12-22 | 2013-01-02 | Roche Glycart Ag | Anticorps anti-her3, et leurs utilisations |
| RU2568051C2 (ru) | 2010-04-09 | 2015-11-10 | Авео Фармасьютикалз, Инк. | АНТИТЕЛА К ErbB3 |
| ES2620255T3 (es) * | 2010-08-20 | 2017-06-28 | Novartis Ag | Anticuerpos para el receptor del factor de crecimiento epidérmico 3 (HER3) |
| MX346486B (es) * | 2011-04-19 | 2017-03-22 | Merrimack Pharmaceuticals Inc | Anticuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos. |
| EP2833915A1 (en) | 2012-04-02 | 2015-02-11 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies |
| EP3107578A2 (en) * | 2014-02-20 | 2016-12-28 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith |
| US20170233491A1 (en) * | 2016-01-19 | 2017-08-17 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment |
-
2012
- 2012-04-19 MX MX2016000234A patent/MX346486B/es unknown
- 2012-04-19 SI SI201230955A patent/SI2699602T1/sl unknown
- 2012-04-19 CA CA2833643A patent/CA2833643A1/en not_active Abandoned
- 2012-04-19 BR BR112013027021A patent/BR112013027021A2/pt not_active Application Discontinuation
- 2012-04-19 CN CN201510472421.9A patent/CN105884900A/zh active Pending
- 2012-04-19 JP JP2014506549A patent/JP5588086B2/ja not_active Expired - Fee Related
- 2012-04-19 TW TW101114063A patent/TWI631136B/zh not_active IP Right Cessation
- 2012-04-19 KR KR1020147031817A patent/KR20140138353A/ko not_active Ceased
- 2012-04-19 CN CN201280028639.XA patent/CN103703026B/zh not_active Expired - Fee Related
- 2012-04-19 KR KR1020137030562A patent/KR101517320B1/ko not_active Expired - Fee Related
- 2012-04-19 ES ES12773950.6T patent/ES2625818T3/es active Active
- 2012-04-19 EP EP17158234.9A patent/EP3214096A3/en not_active Withdrawn
- 2012-04-19 HR HRP20170713TT patent/HRP20170713T1/hr unknown
- 2012-04-19 US US13/451,135 patent/US8476409B2/en active Active
- 2012-04-19 PT PT127739506T patent/PT2699602T/pt unknown
- 2012-04-19 MX MX2013012201A patent/MX336197B/es unknown
- 2012-04-19 WO PCT/US2012/034244 patent/WO2012145507A2/en not_active Ceased
- 2012-04-19 PL PL12773950T patent/PL2699602T3/pl unknown
- 2012-04-19 EP EP12773950.6A patent/EP2699602B1/en active Active
- 2012-04-19 HU HUE12773950A patent/HUE034276T2/en unknown
- 2012-04-19 DK DK12773950.6T patent/DK2699602T3/en active
- 2012-04-19 AU AU2012245491A patent/AU2012245491C1/en not_active Ceased
-
2013
- 2013-02-27 US US13/778,984 patent/US9556274B2/en not_active Expired - Fee Related
- 2013-10-17 IL IL228957A patent/IL228957A0/en unknown
-
2014
- 2014-04-09 JP JP2014080445A patent/JP6214453B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-17 US US14/857,344 patent/US9527914B2/en not_active Expired - Fee Related
-
2016
- 2016-08-26 US US15/248,562 patent/US9938346B2/en active Active
- 2016-10-10 HK HK16111680.4A patent/HK1223383A1/zh unknown
-
2017
- 2017-08-16 AU AU2017216490A patent/AU2017216490A1/en not_active Abandoned